<DOC>
	<DOCNO>NCT01195974</DOCNO>
	<brief_summary>This study two-period , double-blind study healthy adult female subject . Each subject participate oral contraceptive Run-in period prior treatment period . The length Run-in Period 28 day longer , depend time subject 's menstrual cycle whether subject take OC . Each subject participate run-in period ( need ) , follow two treatment period . Treatment Periods 1 2 must conduct successively . Subjects randomize cross-over fashion either YASMIN GSK2248761 Placebo 10 day switch GSK2248761 placebo another 10 day . Subjects return study center final follow evaluation 7 - 14 day final dose study medication .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics Oral Contraceptive When Co-administered With GSK2248761 Healthy Adult Female Subjects .</brief_title>
	<detailed_description>ViiV Healthcare new sponsor study , GlaxoSmithKline process update system reflect change sponsorship</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Drospirenone ethinyl estradiol combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>AST , ALT , alkaline phosphatase bilirubin less equal 1.5xULN ( isolate bilirubin great 1.5xUpper limit normal acceptable bilirubin fractionate direct bilirubin le 35 % ) . Healthy female subject , determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Female , 18 40 year age inclusive , time signing informed consent . Women childbearing potential must use follow appropriate contraceptive method : oral contraceptive YASMIN combination complete abstinence intercourse least 14 day prior first dose investigational product ( Day 1 Period 1 ) , throughout study , subsequent post study monitoring ; YASMIN combination barrier method plus spermicide ( e.g. , condom diaphragm spermicidal foam/gel/cream/ suppository least 14 day prior first dose investigational product [ Day 1 Period 1 ] ) throughout study , subsequent post study monitoring ; Sterilization ( vasectomy ) male partner prior commencement female subject 's last normal menstrual period prior administration study drug , male partner sole partner female subject ; The subject 's Body Mass Index 19 30 killograms/millimeters square body weight great equal 50 kilogram ( 110 pound ) less 114 kilogram ( less 250 pound ) ; Capable give write informed consent , include compliance requirement restriction list consent form ; Single QTc , QTcB QTcF le 450 msec ; QTc le 480 msec subject Bundle Branch Block A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . A positive test HIV antibody . History regular alcohol consumption within 6 month study define : average weekly intake &gt; 7 drink female . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mililiters within 56 day period . Women childbearing potential unwilling unable use appropriate method contraception least 14 day prior first dose investigational product completion followup visit ; Pregnant female determine positive hCG test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . History condition would contraindicate OC administration ( include hypertension , stroke , ischemic heart disease , venous thromboembolism , carcinoma breast , etc . ) ; History sensitivity heparin heparininduced thrombocytopenia . Subjects asthma history asthma , ( e.g. , FTIH risk bronchoconstriction unknown , compound specific risk bronchoconstriction ) . Consumption red wine , Seville oranges , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>oral contraceptive , drug interaction , pharmacokinetics</keyword>
</DOC>